Nouvelle déclaration d'incident
No de la demande: 2020-3426
Numéro de référence du titulaire d'homologation: 2020-US-010368
Nom du titulaire (nom légal complet, aucune abbréviation): The Hartz Mountain Corporation
Adresse: 400 Plaza Drive
Ville: Secaucus
État: New Jersey
Pays: USA
Code postal /Zip: 07094-3688
Incident chez un animal domestique
Pays: UNITED STATES
État: UNKNOWN
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 2596-168
Nom du produit: Hartz UltraGuard Dual Action Topical Flea and Tick Prevention for Dogs
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 2596-125
Nom du produit: Hartz UltraGuard Flea and Tick Spray for Dogs
Liquide
Oui
Inconnu
Site: Animal / Usage sur un animal domestique
Non
Propriétaire de l'animal
Dog / Chien
Yorkshire Terrier
1
Homme
5
5
lbs
Cutanée
>8 hrs <= 24 hrs / >8 h <= 24 h
>8 hrs <=24 hrs / > 8 h < = 24 h
Système
Persisted until death
Non
Non
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 03-May-2020, a 5 year old, 5 pound, neutered, male, Yorkshire Terrier dog, in unknown condition, with no known concomitant medical condition, was administered 1 application of Hartz UltraGuard Dual Action Topical Flea and Tick Prevention for Dogs and Puppies 5-14lb (Etofenprox / N-Octyl-Bicycloheptene Dicarboximide (MGK-264) / Piperonyl Butoxide / Pyriproxifen) via the topical route by the animal owner. Approximately three hours later, the dog was also administered 1 application of Hartz UltraGuard Flea and Tick Spray for Dogs 16oz (Tetrachlorvinphos) via the topical route by the animal owner. This is an extra label use as the products are not intended to be used simultaneously. On 04-May-2020, the dog was found dead and was buried. The dog had not been evaluated by a veterinarian, no treatment had been performed and no necropsy had been performed.
Mort
Assessment: Both products are considered to have a wide margin of safety in dogs. Although they are not intended to be applied simultaneously, severe signs, including sudden death are not expected. Other causes should be considered including underlying disease, unknown trauma, or other unknown exposures. No diagnostics including necropsy occurred so the cause of death is unknown. The information contained in this report is based on self-reported statements provided to the registrant during telephone interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.